Trial Profile

A Phase 1 Study of NKX101, an Activating Chimeric Receptor Natural Killer Cell Therapy, in Subjects With Hematological Malignancies or Dysplasias

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs NKX 101 (Primary) ; Cyclophosphamide; Cytarabine; Decitabine; Fludarabine
Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Nkarta Therapeutics

Most Recent Events

08 Apr 2024 Status changed from recruiting to active, no longer recruiting.
12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition
10 Dec 2023 Follow-up data presented in the Nkarta Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com